Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

874 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A double-blind, randomized, placebo and active-controlled study of nebicapone for the treatment of motor fluctuations in Parkinson's disease.
Ferreira JJ, Rascol O, Poewe W, Sampaio C, Rocha JF, Nunes T, Almeida L, Soares-da-Silva P; BIA-3202-202 Study Investigators. Ferreira JJ, et al. Among authors: poewe w. CNS Neurosci Ther. 2010 Dec;16(6):337-47. doi: 10.1111/j.1755-5949.2010.00145.x. CNS Neurosci Ther. 2010. PMID: 20653695 Free PMC article. Clinical Trial.
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan.
Goetz CG, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stebbins GT, Stern MB, Tilley BC, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, Van Hilten JJ, LaPelle N. Goetz CG, et al. Among authors: poewe w. Mov Disord. 2007 Jan;22(1):41-7. doi: 10.1002/mds.21198. Mov Disord. 2007. PMID: 17115387
Depression rating scales in Parkinson's disease: critique and recommendations.
Schrag A, Barone P, Brown RG, Leentjens AF, McDonald WM, Starkstein S, Weintraub D, Poewe W, Rascol O, Sampaio C, Stebbins GT, Goetz CG. Schrag A, et al. Among authors: poewe w. Mov Disord. 2007 Jun 15;22(8):1077-92. doi: 10.1002/mds.21333. Mov Disord. 2007. PMID: 17394234 Free PMC article.
A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics.
Olanow CW, Hauser RA, Jankovic J, Langston W, Lang A, Poewe W, Tolosa E, Stocchi F, Melamed E, Eyal E, Rascol O. Olanow CW, et al. Among authors: poewe w. Mov Disord. 2008 Nov 15;23(15):2194-201. doi: 10.1002/mds.22218. Mov Disord. 2008. PMID: 18932271 Clinical Trial.
A double-blind, delayed-start trial of rasagiline in Parkinson's disease.
Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, Langston W, Melamed E, Poewe W, Stocchi F, Tolosa E; ADAGIO Study Investigators. Olanow CW, et al. Among authors: poewe w. N Engl J Med. 2009 Sep 24;361(13):1268-78. doi: 10.1056/NEJMoa0809335. N Engl J Med. 2009. PMID: 19776408 Free article. Clinical Trial.
874 results